The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial cancer, a recent phase 3 trial found.

“It’s not OK for them to dismiss it like that.” Uterine is the only cancer for which survival has fallen in the past four ...

Endometrial, or uterine, cancer affects more than 60,000 women in the U.S. each year. It is one of the few cancers in which incidence is increasing. Survival for early-stage endometrial cancer ...

Uterine cancer, which often begins in the lining—or endometrium—of the uterus, is the most common cancer of the female reproductive system and usually occurs in people over age 55. Learn more ...

At the ASCO 2024, four clinically very important abstracts in endometrial cancer were presented. Long-term survival for ...

all patients with primary advanced or recurrent endometrial cancer in the EU have an approved immuno-oncology-based treatment that has shown a statistically significant and clinically meaningful ...

Lenvima plus Keytruda did not significantly improve survival or progression-free survival compared to chemotherapy in advanced endometrial cancer. The study involved 842 patients, with no new safety ...

European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...